Bill Gates published an insightful memo that outlines his view on the COVID-19 pandemic. He addresses the initial outbreak with an explanation of exponential growth and decline and whether the…
Competition among colleagues in science advances knowledge in the field, pushes boundaries, and leads to the production of new therapeutics. Often, companies compete against each other to develop the next…
Once again, the journal mAbs has published its 11th annual “Antibodies to Watch” article as an overview of exciting antibody products staged for significant advances in the coming year, authored…
South San Francisco is home to the largest biotech cluster in the world, with over 200 biotech companies, and 11.5-million square feet of biotech space on 500 acres. But 16…
Monoclonal antibodies (mAbs) as a therapeutic modality were developed over an 11-year period, from the first production of mAbs in 1975 to the first licensing of mAb therapeutic Orthoclone OKT3…
After the 2014 Ebola outbreak in West Africa, researchers wanted to test ZMapp, a new, experimental drug that had been used during that outbreak on some infected patients, along with…
The approval of Zolgensma (onasemnogene abeparvovexioi) in May of this year was quite a milestone for the Cell and Gene Therapy world. Zolgensma is an Adenovirus Associated Virus (AAV)-based gene…
One of the most challenging aspects in developing new mAb therapeutics is target discovery. Identification of new, validated and preferably functional targets is difficult to sustain and is clearly a…
The annual “Antibodies to Watch” article series is celebrating its 10th anniversary. Published in the journal mAbs and widely anticipated at the beginning of the new year, these articles have…
Nancy Bradish Myers of Catalyst Healthcare Consulting in Washington, D.C., knows FDA well and recently assessed the impact of the US government shutdown on FDA. Here’s what is happening now,…